



13 August 2025



PolyNovo Limited ABN 96 083 866 862

2/320 Lorimer Street Port Melbourne VIC Australia 3207

P +61 (0) 3 8681 4050 F +61 (0) 3 8681 4099

ASX Announcement

FY25 Results Presentation

The Company's FY25 results presentation will be live streamed on Monday, 25 August at 2.00 pm AEST.

To access the webcast, shareholders will need to register at the following website prior to commencement of the presentation:

https://event.choruscall.com/mediaframe/webcast.html?webcastid=Xiq2GRJe

Shareholders who would like to ask a question are asked to email their question to investor@polynovo.com in advance of the event. We will endeavour to answer your question prior to, or during, the webcast.

Alternatively, shareholders can ask questions live during the webcast via the webcast platform.

Broker analysts who cover the Company can ask questions live.

This announcement has been authorised by Company Secretary Jan Gielen.

About PolyNovo®

PolyNovo is a disruptive ASX 200 medical technology company, based in Melbourne, Australia. Its products simplify management of acute complex wounds, redefining healing with meaningfully differentiated patient outcomes across multiple wound etiologies. After treating 70,000+ patients across 46 countries, the company is investing for growth with new products, indications, and markets. For more information see polynovo.com.

About NovoSorb®

NovoSorb BTM is a dermal scaffold for the regeneration of the dermis when lost through surgery, trauma or burn. NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.